Cipla says DRI conducts search at Mumbai office, Bhiwandi depot over imported drug

Resumen detallado
Cipla said it extended full cooperation and assistance to the authorities during the proceedings. The company added that the search would have no material impact on its financials, operations or other activities.
Homegrown pharma major Cipla Ltd on Monday (November 16) said the Directorate of Revenue Intelligence (DRI), Mumbai Zonal Unit, conducted search proceedings at its office in Vikhroli, Mumbai, and depot in Bhiwandi, Thane, Maharashtra, in connection with the classification and exemption of an imported pharmaceutical finished product.
"...we hereby notify that the Directorate of Revenue Intelligence, Mumbai zonal unit, on 16 November 2026 conducted a search proceeding at the Company’s office located in Vikhroli, Mumbai, Maharashtra and at its depot located in Bhiwandi, Thane, Maharashtra. The Company extended its full co-operation and assistance in this regard," according to a stock exchange filing.
The search was initiated and concluded on November 16 under Section 105 of the Customs Act, 1962, the pharmaceutical company said.
ALSO READ | Cipla shares gain after it inks cancer treatment drug licensing deal with Sino Biopharma arm
Cipla said it extended full cooperation and assistance to the authorities during the proceedings. The company added that the search would have no material impact on its financials, operations or other activities.
Cipla's net profit declined 35% year-on-year to ₹878 crore, falling short of the CNBC-TV18 poll estimate of ₹949 crore. The decline was attributed to lower other income and higher expenses. Revenue for the quarter fell 2.4% from a year earlier to ₹7,404 crore, compared with the Street estimate of ₹7,498 crore.
Earnings before interest, tax, depreciation and amortisation (EBITDA) declined 26.7% year-on-year to ₹1,388 crore from ₹1,894.75 crore in the corresponding quarter last year. However, the figure was marginally ahead of the CNBC-TV18 poll estimate of ₹1,371 crore.o
ALSO READ | Deven Choksey prefers Sun Pharma, Cipla for fresh buying; sees upside in Indian IT
Cipla’s EBITDA margin contracted 630 basis points year-on-year to 18.7%, from 25% in the year-ago quarter. The margin, however, was above the CNBC-TV18 poll estimate of 18.3%.
Inicio del artículo, extracto de CNBC-TV18. Para leer el resto, abra el artículo en el sitio del medio.
MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.cnbctv18.com)




